• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

凝血酶激活的纤溶酶原激活剂的设计与评估

Design and evaluation of a thrombin-activable plasminogen activator.

作者信息

Yang W P, Goldstein J, Procyk R, Matsueda G R, Shaw S Y

机构信息

Department of Macromolecular Biochemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000.

出版信息

Biochemistry. 1994 Mar 1;33(8):p606-12. doi: 10.1021/bi00174a043.

DOI:10.1021/bi00174a043
PMID:8117652
Abstract

A new chimeric plasminogen activator with high fibrin affinity was designed to bind fibrin and to initiate clot destruction, following activation by thrombin. The chimeric activator, 59D8-scuPA-T, was made from the Fab fragment of an anti-fibrin antibody (59D8) and a C-terminal portion of a thrombin-activable low molecular weight single-chain urokinase plasminogen activator, scuPA-T, obtained by deletion of Phe-157 and Lys-158 from low molecular weight single-chain urokinase-type plasminogen activator (scuPA) by site-directed mutagenesis. The chimeric molecule had a molecular mass of 91,000, a value consistent with one 59D8 light chain (M(r) = 27,000) and one 59D8 heavy-chain Fd fragment fused to low molecular weight scuPA (M(r) = 64,000). According to its design, 59D8-scuPA-T was activated by thrombin but not by plasmin, whereas the control chimeric molecule, 59D8-scuPA, was activated by plasmin but not by thrombin. When activated by thrombin, 59D8-scuPA-T converted plasminogen to plasmin. In vitro plasma clot lysis assays showed that 59D8-scuPA-T lysed clots performed by thrombin and that heparin and hirudin could prevent clot lysis. When incorporated as part of a thrombin-induced clot, only 59D8-scuPA-T was able to lyse the clot while 59D8-scuPA and high molecular weight scuPA were ineffective. Together these results demonstrate that 59D8-scuPA-T is a thrombin-activable plasminogen activator that offers selective thrombolysis of thrombin-rich clots over more established, aged clots, and may also act as an antithrombotic agent.

摘要

设计了一种具有高纤维蛋白亲和力的新型嵌合纤溶酶原激活剂,使其在被凝血酶激活后能够结合纤维蛋白并启动血栓溶解。嵌合激活剂59D8 - scuPA - T由抗纤维蛋白抗体(59D8)的Fab片段和凝血酶可激活的低分子量单链尿激酶型纤溶酶原激活剂scuPA - T的C末端部分组成,scuPA - T是通过定点诱变从低分子量单链尿激酶型纤溶酶原激活剂(scuPA)中缺失苯丙氨酸 - 157和赖氨酸 - 158而获得的。该嵌合分子的分子量为91,000,这一数值与一条59D8轻链(M(r)=27,000)和一条与低分子量scuPA(M(r)=64,000)融合的59D8重链Fd片段一致。根据其设计,59D8 - scuPA - T可被凝血酶激活但不能被纤溶酶激活,而对照嵌合分子59D8 - scuPA可被纤溶酶激活但不能被凝血酶激活。当被凝血酶激活时,59D8 - scuPA - T可将纤溶酶原转化为纤溶酶。体外血浆凝块溶解试验表明,59D8 - scuPA - T可溶解由凝血酶形成的凝块,并且肝素和水蛭素可阻止凝块溶解。当作为凝血酶诱导凝块的一部分掺入时,只有59D8 - scuPA - T能够溶解凝块,而59D8 - scuPA和高分子量scuPA均无效。这些结果共同表明,59D8 - scuPA - T是一种可被凝血酶激活的纤溶酶原激活剂,与更成熟、老化的凝块相比,它能对富含凝血酶的凝块进行选择性溶栓,并且还可能作为一种抗血栓形成剂。

相似文献

1
Design and evaluation of a thrombin-activable plasminogen activator.凝血酶激活的纤溶酶原激活剂的设计与评估
Biochemistry. 1994 Mar 1;33(8):p606-12. doi: 10.1021/bi00174a043.
2
Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase.一种由抗纤维蛋白单链抗体和低分子量尿激酶组成的重组纤溶酶原激活剂的构建与表征
J Thromb Haemost. 2004 May;2(5):797-803. doi: 10.1111/j.1538-7836.2004.00697.x.
3
A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo.一种对纤维蛋白具有高亲和力的重组嵌合纤溶酶原激活剂在体外和体内均具有增强的溶栓效力。
Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10337-41. doi: 10.1073/pnas.88.22.10337.
4
Construction and characterization of a recombinant chimeric plasminogen activator consisting of a fibrin peptide and a low molecular mass single-chain urokinase.一种由纤维蛋白肽和低分子量单链尿激酶组成的重组嵌合型纤溶酶原激活剂的构建与特性分析
Biochimie. 2001 Nov-Dec;83(11-12):1049-55. doi: 10.1016/s0300-9084(01)01352-9.
5
A chimeric streptokinase with unexpected fibrinolytic selectivity.一种具有意外纤维蛋白溶解选择性的嵌合链激酶。
Thromb Haemost. 1996 Sep;76(3):429-38.
6
Lysis of plasma clots by urokinase-soluble urokinase receptor complexes.尿激酶-可溶性尿激酶受体复合物对血浆凝块的溶解作用。
Blood. 1998 Sep 15;92(6):2075-83.
7
Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.由纤维蛋白特异性抗体的单链Fv片段和单链尿激酶组成的单链嵌合纤溶酶原激活剂的生化特性
Eur J Biochem. 1992 Dec 15;210(3):945-52. doi: 10.1111/j.1432-1033.1992.tb17499.x.
8
Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons.一种纤维蛋白靶向纤溶酶原激活剂在狒狒体内增强的溶栓和抗血栓效力。
Circulation. 1996 Sep 15;94(6):1412-22. doi: 10.1161/01.cir.94.6.1412.
9
Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.纤维蛋白靶向对尿激酶型纤溶酶原激活剂溶栓作用的影响。
Thromb Res. 1990 Feb 1;57(3):333-42. doi: 10.1016/0049-3848(90)90249-c.
10
Hybrid molecules: insights into plasminogen activator function.杂合分子:对纤溶酶原激活物功能的见解
Mol Biol Med. 1991 Apr;8(2):245-55.

引用本文的文献

1
Targeted endothelial nanomedicine for common acute pathological conditions.针对常见急性病理状况的靶向内皮纳米药物
J Control Release. 2015 Dec 10;219:576-595. doi: 10.1016/j.jconrel.2015.09.055. Epub 2015 Oct 3.
2
Advanced drug delivery systems for antithrombotic agents.抗血栓药物的先进药物递送系统。
Blood. 2013 Aug 29;122(9):1565-75. doi: 10.1182/blood-2013-03-453498. Epub 2013 Jun 24.
3
Vascular targeting of antithrombotic agents.抗血栓药物的血管靶向作用。
IUBMB Life. 2011 Aug;63(8):632-9. doi: 10.1002/iub.474. Epub 2011 Jul 15.
4
Targeting antioxidant and antithrombotic biotherapeutics to endothelium.针对血管内皮的抗氧化和抗血栓生物治疗。
Semin Thromb Hemost. 2010 Apr;36(3):332-42. doi: 10.1055/s-0030-1253455. Epub 2010 May 20.
5
Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.在血栓形成部位激活的红细胞靶向促尿激酶原酶促物介导的持续抗栓治疗。
Blood. 2010 Jun 24;115(25):5241-8. doi: 10.1182/blood-2010-01-261610. Epub 2010 Apr 21.
6
Targeted delivery of therapeutics to endothelium.将治疗药物靶向递送至内皮细胞。
Cell Tissue Res. 2009 Jan;335(1):283-300. doi: 10.1007/s00441-008-0676-7. Epub 2008 Sep 25.
7
Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature.通过靶向肺血管中PECAM-1的凝血酶激活潜伏型尿激酶原进行预防性溶栓。
Blood. 2008 Feb 15;111(4):1999-2006. doi: 10.1182/blood-2007-07-103002. Epub 2007 Nov 28.
8
Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis.通过人补体受体1将组织纤溶酶原激活剂负载于循环红细胞上进行预防性纤维蛋白溶解。
Blood. 2006 Sep 15;108(6):1895-902. doi: 10.1182/blood-2005-11-012336. Epub 2006 May 30.
9
Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature.将PECAM-1单链可变抗体片段(scFv)与尿激酶原融合的重组构建体靶向内皮细胞,有助于在肺血管系统中进行预防性溶栓。
Blood. 2005 Dec 15;106(13):4191-8. doi: 10.1182/blood-2005-05-2002. Epub 2005 Sep 6.